429 related articles for article (PubMed ID: 22104275)
21. Clustering of cardio-metabolic risk factors and pre-diabetes among U.S. adolescents.
Liu C; Wu S; Pan X
Sci Rep; 2021 Mar; 11(1):5015. PubMed ID: 33658537
[TBL] [Abstract][Full Text] [Related]
22. The metabolic syndrome increased risk of cardiovascular events in Chinese--a community based study.
Wang C; Hou X; Bao Y; Pan J; Zuo Y; Zhong W; Jia W; Xiang K
Int J Cardiol; 2010 Mar; 139(2):159-65. PubMed ID: 19046783
[TBL] [Abstract][Full Text] [Related]
23. Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes.
Taskinen MR; Barter PJ; Ehnholm C; Sullivan DR; Mann K; Simes J; Best JD; Hamwood S; Keech AC;
Diabetologia; 2010 Sep; 53(9):1846-55. PubMed ID: 20526762
[TBL] [Abstract][Full Text] [Related]
24. Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes.
Elam MB; Ginsberg HN; Lovato LC; Corson M; Largay J; Leiter LA; Lopez C; O'Connor PJ; Sweeney ME; Weiss D; Friedewald WT; Buse JB; Gerstein HC; Probstfield J; Grimm R; Ismail-Beigi F; Goff DC; Fleg JL; Rosenberg Y; Byington RP;
JAMA Cardiol; 2017 Apr; 2(4):370-380. PubMed ID: 28030716
[TBL] [Abstract][Full Text] [Related]
25. Metabolic syndrome and cardiovascular disease in older people: The cardiovascular health study.
McNeill AM; Katz R; Girman CJ; Rosamond WD; Wagenknecht LE; Barzilay JI; Tracy RP; Savage PJ; Jackson SA
J Am Geriatr Soc; 2006 Sep; 54(9):1317-24. PubMed ID: 16970637
[TBL] [Abstract][Full Text] [Related]
26. Favourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
d'Emden MC; Jenkins AJ; Li L; Zannino D; Mann KP; Best JD; Stuckey BG; Park K; Saltevo J; Keech AC;
Diabetologia; 2014 Nov; 57(11):2296-303. PubMed ID: 25149070
[TBL] [Abstract][Full Text] [Related]
27. The usefulness of the International Diabetes Federation and the National Cholesterol Education Program's Adult Treatment Panel III definitions of the metabolic syndrome in predicting coronary heart disease in subjects with type 2 diabetes.
Tong PC; Kong AP; So WY; Yang X; Ho CS; Ma RC; Ozaki R; Chow CC; Lam CW; Chan JC; Cockram CS
Diabetes Care; 2007 May; 30(5):1206-11. PubMed ID: 17259472
[TBL] [Abstract][Full Text] [Related]
28. Prevalence of Metabolic Syndrome by different definitions, and its association with type 2 diabetes, pre-diabetes, and cardiovascular disease risk in Brazil.
do Vale Moreira NC; Hussain A; Bhowmik B; Mdala I; Siddiquee T; Fernandes VO; Montenegro Júnior RM; Meyer HE
Diabetes Metab Syndr; 2020; 14(5):1217-1224. PubMed ID: 32682310
[TBL] [Abstract][Full Text] [Related]
29. Non-traditional markers of atherosclerosis potentiate the risk of coronary heart disease in patients with type 2 diabetes and metabolic syndrome.
Bianchi C; Penno G; Malloggi L; Barontini R; Corfini M; Giovannitti MG; Di Cianni G; Del Prato S; Miccoli R
Nutr Metab Cardiovasc Dis; 2008 Jan; 18(1):31-8. PubMed ID: 17420118
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of coadministration of fenofibrate and ezetimibe compared with each as monotherapy in patients with type IIb dyslipidemia and features of the metabolic syndrome: a prospective, randomized, double-blind, three-parallel arm, multicenter, comparative study.
Ansquer JC; Bekaert I; Guy M; Hanefeld M; Simon A;
Am J Cardiovasc Drugs; 2009; 9(2):91-101. PubMed ID: 19331437
[TBL] [Abstract][Full Text] [Related]
31. The NCEP-ATPIII but not the IDF criteria for the metabolic syndrome identify Type 2 diabetic patients at increased risk of chronic kidney disease.
Luk AO; Ma RC; So WY; Yang XL; Kong AP; Ozaki R; Ko GT; Chow CC; Cockram CS; Chan JC; Tong PC
Diabet Med; 2008 Dec; 25(12):1419-25. PubMed ID: 19046240
[TBL] [Abstract][Full Text] [Related]
32. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men.
Lakka HM; Laaksonen DE; Lakka TA; Niskanen LK; Kumpusalo E; Tuomilehto J; Salonen JT
JAMA; 2002 Dec; 288(21):2709-16. PubMed ID: 12460094
[TBL] [Abstract][Full Text] [Related]
33. HDL Cholesterol as a Residual Risk Factor for Vascular Events and All-Cause Mortality in Patients With Type 2 Diabetes.
Sharif S; van der Graaf Y; Nathoe HM; de Valk HW; Visseren FL; Westerink J;
Diabetes Care; 2016 Aug; 39(8):1424-30. PubMed ID: 27222511
[TBL] [Abstract][Full Text] [Related]
34. Metabolic syndrome and 10-year cardiovascular disease incidence: The ATTICA study.
Kastorini CM; Panagiotakos DB; Georgousopoulou EN; Laskaris A; Skourlis N; Zana A; Chatzinikolaou C; Chrysohoou C; Puddu PE; Tousoulis D; Stefanadis C; Pitsavos C;
Nutr Metab Cardiovasc Dis; 2016 Mar; 26(3):223-31. PubMed ID: 26803591
[TBL] [Abstract][Full Text] [Related]
35. [Prevalence of metabolic syndrome using NCEP-ATPIII and IDF definitions in Brazilian individuals].
Nakazone MA; Pinheiro A; Braile MC; Pinhel MA; de Sousa GF; Pinheiro S; Brandão AC; Toledo JC; Braile DM; Souza DR
Rev Assoc Med Bras (1992); 2007; 53(5):407-13. PubMed ID: 17952349
[TBL] [Abstract][Full Text] [Related]
36. Management of cardiovascular risk in patients with type 2 diabetes mellitus as a component of the cardiometabolic syndrome.
Ferdinand KC
J Cardiometab Syndr; 2006; 1(2):133-40. PubMed ID: 17679832
[TBL] [Abstract][Full Text] [Related]
37. High prevalence of abdominal obesity increases the risk of the metabolic syndrome in Nigerian type 2 diabetes patients: using the International Diabetes Federation worldwide definition.
Ezenwaka CE; Okoye O; Esonwune C; Onuoha P; Dioka C; Osuji C; Oguejiofor C; Meludu S
Metab Syndr Relat Disord; 2014 Jun; 12(5):277-82. PubMed ID: 24601861
[TBL] [Abstract][Full Text] [Related]
38. Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus.
Keating GM
Am J Cardiovasc Drugs; 2011 Aug; 11(4):227-47. PubMed ID: 21675801
[TBL] [Abstract][Full Text] [Related]
39. Associations between the use of metformin, sulphonylureas, or diet alone and cardiovascular outcomes in 6005 people with type 2 diabetes in the FIELD study.
Sullivan D; Forder P; Simes J; Whiting M; Kritharides L; Merrifield A; Donoghoe M; Colman PG; Graham N; Haapamäki H; Keech A;
Diabetes Res Clin Pract; 2011 Nov; 94(2):284-90. PubMed ID: 21862166
[TBL] [Abstract][Full Text] [Related]
40. Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
Drury PL; Ting R; Zannino D; Ehnholm C; Flack J; Whiting M; Fassett R; Ansquer JC; Dixon P; Davis TM; Pardy C; Colman P; Keech A
Diabetologia; 2011 Jan; 54(1):32-43. PubMed ID: 20668832
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
